Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$31.26

1.18 (3.92%)

, CATB

Catabasis Pharmaceuticals

$4.13

-0.11 (-2.59%)

11:13
01/10/17
01/10
11:13
01/10/17
11:13

Sarepta surges following update on Exondys 51 launch

Shares of Sarepta Therapeutics (SRPT) surged higher after the company disclosed sales data for the launch of its Duchenne muscular dystrophy drug Exondys 51. Sales of the drug hit $5.4M as of December 31, 2016, Sarepta reported at today's JPMorgan Healthcare Conference. The company also stated that a majority of insurance plans are covering or evaluating coverage on a case-by-case basis. Only 8% of Covered Lives are denying converge while 79% are pending policy decisions, Sarepta CEO Edward Kaye said today. He notes that over 250 genetically verified start forms have been submitted since the launch of Exondys 51. The company, for the first time, also disclosed data in mice for its next generation antisense platform, PPMO. The data show improved delivery in vivo and "superior" dystrophin, Kaye told the audience. Sarepta expects to dose PPMO in humans by the end of 2017. Sarepta shares are up 13% to $35.46 in morning trading. Catabasis Pharmaceuticals (CATB) is up 7% to $4.44. The two companies last September announced a joint research collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy.

SRPT

Sarepta

$31.26

1.18 (3.92%)

CATB

Catabasis Pharmaceuticals

$4.13

-0.11 (-2.59%)

  • 10

    Jan

SRPT Sarepta
$31.26

1.18 (3.92%)

12/22/16
JPMS
12/22/16
INITIATION
Target $40
JPMS
Overweight
Sarepta initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Sarepta Therapeutics with an Overweight rating and $40 price target. The stock is down over 50% since the September approval of Exondys 51 for the treatment of Exon 51 Duchenne muscular dystrophy, Rama tells investors in a research note. The analyst believes that while shares could be range-bound in the first half of 2017 amid a "conservative launch trajectory" relative to consensus expectations, Sarepta "could be poised for a rebound" in the second half of the year as it works work with payers and provides greater clarity. He thinks "patience will be required" for Sarepta investors.
12/22/16
12/22/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Microsoft (MSFT) initiated with an Overweight at Piper Jaffray. 2. Sarepta (SRPT) initiated with an Overweight at JPMorgan. 3. Oracle (ORCL) initiated with an Overweight at MUFG. 4. Zillow (Z, ZG) initiated with a Hold at Stifel. 5. Las Vegas Sands (LVS) was initiated with a Buy and Wynn Resorts (WYNN) was initiated with a Neutral at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/23/16
OPCO
12/23/16
NO CHANGE
Target $76
OPCO
Outperform
Oppenheimer remains bullish on Sarepta
Oppenheimer analyst Hartaj Singh notes that Sarepta has a commercial and active product in Exondys 51 for Exon 51 amenable Duchenne muscular dystrophy, a disease with a high unmet need. The analyst believes that a "complex reimbursement environment" coupled with a small target patient population in the U.S. could lead to a slower launch than expected. However, once the reimbursement process is settled and the patient on-boarding process is efficient, he expects a stronger sales ramp. Singh remains bullish on the stock, and reiterates an Outperform rating and $76 price target on the shares.
01/06/17
JMPS
01/06/17
NO CHANGE
Target $65
JMPS
Outperform
Sarepta price target lowered to $65 after physician survey at JMP Securities
JMP Securities analyst Liisa Bayko reported the firm conducted its first survey of U.S. physicians who treat Duchenne muscular dystrophy patients to gauge early experiences with Sarepta's Exondys 51. At the end of 2016, respondents had written a prescription to about 1 in 5 eligible patients, 1 in 5 were denied coverage and about 15% were in the adjudication process, noted Bayko, who lowered her price target on Sarepta to $65 from $90 to adjust for the survey results as well as an updated pricing analysis. Bayko keeps an Outperform rating on Sarepta and said she sees potential upside to about $160 per share if Exondys 51 is approved in the EU and if all of its earlier-stage assets targeting exons 45/53 are successful.
CATB Catabasis Pharmaceuticals
$4.13

-0.11 (-2.59%)

06/09/16
SBSH
06/09/16
NO CHANGE
Target $8
SBSH
Buy
Catabasis Pharmaceuticals price target lowered to $8 from $16 at Citi
Citi analyst Joel Beatty halved his price target for Catabasis Pharmaceuticals to $8 and removed CAT-2054 from his model after the agent failed to lower cholesterol on top of statins in a Phase 2 trial. The analyst, however, continues to see favorable risk/reward into Phase 2 data in late 2016 for lead agent CAT-1004 in Duchenne Muscular Dystrophy. Beatty keeps a Buy rating on Catabasis.
11/11/16
COWN
11/11/16
NO CHANGE
Target $30
COWN
Outperform
Catabasis Pharmaceuticals shares remain undervalued, says Cowen
Cowen analyst Phil Nadeau believes Catabasis Pharmaceuticals shares remain undervalued based on the potential of edasalonexent. The analyst said the company's proof-of-concept data will be released in Q1. Nadeau maintained his Outperform rating and $30 price target on Catabasis Pharmaceuticals shares.
12/22/16
HCWC
12/22/16
INITIATION
Target $14
HCWC
Buy
Catabasis Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther started Catabasis Pharmaceuticals with a Buy rating and $14 price target. Edasalonexent is an oral agent that has the potential to treat all 50,000 Duchenne muscular dystrophy patients in the developed world, Werther tells investors in a research note. She believes the drug may reach the U.S. and European markets in 2021.
01/04/17
OPCO
01/04/17
NO CHANGE
Target $18
OPCO
Outperform
Catabasis approaching 'important inflection point,' says Oppenheimer
Oppenheimer analyst Hartaj Singh believes Catabasis Pharmaceuticals is approaching an "important inflection point," with Phase 1/2 MoveDMD Part B top-line data release in the first half of Q1. The analyst notes that a positive MoveDMD trial should lead to a pivotal Phase 3 trial being initiated by the company later in 2017. He reiterated an Outperform rating on the stock, but lowered his price target on the shares to $18 from $23 on valuation.

TODAY'S FREE FLY STORIES

02:40
01/18/17
01/18
02:40
01/18/17
02:40
General news
FX Update: The dollar recouped some of yesterday's lost ground »

FX Update: The dollar…

C

Citi

$58.38

-1.25 (-2.10%)

, GS

Goldman Sachs

$235.74

-8.56 (-3.50%)

20:25
01/17/17
01/17
20:25
01/17/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

C

Citi

$58.38

-1.25 (-2.10%)

GS

Goldman Sachs

$235.74

-8.56 (-3.50%)

USB

U.S. Bancorp

$50.31

-1.38 (-2.67%)

AMTD

TD Ameritrade

$45.87

-0.99 (-2.11%)

NTRS

Northern Trust

$88.15

-2.04 (-2.26%)

FAST

Fastenal

$48.26

0.205 (0.43%)

CBSH

Commerce Bancshares

$55.90

-2.02 (-3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 25

    Jan

  • 26

    Jan

  • 15

    Mar

TOSBF

Toshiba, also use TOSYY

$2.60

0.094709 (3.77%)

, TOSYY

Toshiba, also use TOSBF

$15.35

0.37 (2.47%)

20:05
01/17/17
01/17
20:05
01/17/17
20:05
Periodicals
Toshiba says considers spinoff of memory chip unit, Bloomberg reports »

Toshiba (TOSBF) is…

TOSBF

Toshiba, also use TOSYY

$2.60

0.094709 (3.77%)

TOSYY

Toshiba, also use TOSBF

$15.35

0.37 (2.47%)

WDC

Western Digital

$71.62

0.62 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

TM

Toyota

$118.41

-1.4 (-1.17%)

, AIQUY

Air Liquide

$21.97

-0.245 (-1.10%)

19:56
01/17/17
01/17
19:56
01/17/17
19:56
Hot Stocks
Thirteen energy, transport, industrial companies launch 'Hydrogen Council' »

Toyota (TM) announced…

TM

Toyota

$118.41

-1.4 (-1.17%)

AIQUY

Air Liquide

$21.97

-0.245 (-1.10%)

ALSMY

Alstom

NGLOY

Anglo American

$8.14

0.1 (1.24%)

BAMXY

BMW Group

DDAIF

Daimler AG

$75.35

-0.24 (-0.32%)

HMC

Honda

$29.66

-0.42 (-1.40%)

HYMLF

Hyundai Motor Co

RDS.A

Royal Dutch Shell

$55.54

0.06 (0.11%)

RDS.B

Royal Dutch Shell

$58.91

0.24 (0.41%)

LNAGF

Linde AG

$161.90

-0.15 (-0.09%)

TOT

Total

$51.51

-0.08 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Feb

NYT

New York Times

$13.50

-0.1 (-0.74%)

19:30
01/17/17
01/17
19:30
01/17/17
19:30
Hot Stocks
New York Times releases internal report on newsroom strategy »

The New York Times has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENRJ

EnerJex Resources

19:19
01/17/17
01/17
19:19
01/17/17
19:19
Hot Stocks
EnerJex announces NYSE acceptance of plan to meet listing standards »

EnerJex Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$235.74

-8.56 (-3.50%)

19:19
01/17/17
01/17
19:19
01/17/17
19:19
Periodicals
Goldman Sachs compliance chief to step down, Reuters says »

Goldman Sachs compliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$16.96

-0.29 (-1.68%)

19:13
01/17/17
01/17
19:13
01/17/17
19:13
Periodicals
Twitter phases out 'buy' button, TechCrunch says »

Twitter appears to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HSBC

HSBC

$41.18

0.02 (0.05%)

19:04
01/17/17
01/17
19:04
01/17/17
19:04
Periodicals
HSBC CEO: Trading ops generating 20% of London revenue may move, Bloomberg says »

HSBC CEO Stuart Gulliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.18

0.02 (0.05%)

19:02
01/17/17
01/17
19:02
01/17/17
19:02
Periodicals
HSBC CEO: 10% RoE may be new goal, Bloomberg says »

HSBC CEO Stuart Gulliver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CWT

California Water Service

$33.05

0.05 (0.15%)

19:01
01/17/17
01/17
19:01
01/17/17
19:01
Initiation
California Water Service initiated  »

California Water Service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AWK

American Water

$72.07

1.25 (1.77%)

19:01
01/17/17
01/17
19:01
01/17/17
19:01
Initiation
American Water initiated  »

American Water initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.60

0.094709 (3.77%)

, TOSYY

Toshiba, also use TOSBF

$15.35

0.37 (2.47%)

18:59
01/17/17
01/17
18:59
01/17/17
18:59
Periodicals
Toshiba: Considering spinning off chip unit, Bloomberg reports »

Responding to a Nikkei…

TOSBF

Toshiba, also use TOSYY

$2.60

0.094709 (3.77%)

TOSYY

Toshiba, also use TOSBF

$15.35

0.37 (2.47%)

WDC

Western Digital

$71.62

0.62 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

KSU

Kansas City Southern

18:57
01/17/17
01/17
18:57
01/17/17
18:57
Initiation
Kansas City Southern initiated  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

NSC

Norfolk Southern

$108.90

-2.69 (-2.41%)

18:57
01/17/17
01/17
18:57
01/17/17
18:57
Initiation
Norfolk Southern initiated  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

UNP

Union Pacific

$103.37

-1.88 (-1.79%)

18:57
01/17/17
01/17
18:57
01/17/17
18:57
Initiation
Union Pacific initiated  »

Union Pacific initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 09

    May

AZO

AutoZone

$782.29

2.48 (0.32%)

18:54
01/17/17
01/17
18:54
01/17/17
18:54
Initiation
AutoZone initiated  »

AutoZone initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORLY

O'Reilly Automotive

$278.76

-0.39 (-0.14%)

18:54
01/17/17
01/17
18:54
01/17/17
18:54
Initiation
O'Reilly Automotive initiated  »

O'Reilly Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

AAP

Advance Auto Parts

$173.00

-1.79 (-1.02%)

18:54
01/17/17
01/17
18:54
01/17/17
18:54
Initiation
Advance Auto Parts initiated  »

Advance Auto Parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTE

Earthstone Energy

$13.40

-0.18 (-1.33%)

18:51
01/17/17
01/17
18:51
01/17/17
18:51
Initiation
Earthstone Energy initiated  »

Earthstone Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.43

1.25 (0.85%)

18:41
01/17/17
01/17
18:41
01/17/17
18:41
Upgrade
McKesson rating change  »

McKesson upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

NRG

NRG Energy

$15.34

0.74 (5.07%)

18:38
01/17/17
01/17
18:38
01/17/17
18:38
Hot Stocks
NRG Energy says 'looks forward to an open dialogue with Elliott and Bluescape' »

NRG Energy received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LMCA

Liberty Media

$28.71

-1.53 (-5.06%)

, LMCK

Liberty Media

$28.72

-1.54 (-5.09%)

18:22
01/17/17
01/17
18:22
01/17/17
18:22
Hot Stocks
Liberty Media holders approve proposals relating to acquisition of Formula 1 »

Liberty Media announced…

LMCA

Liberty Media

$28.71

-1.53 (-5.06%)

LMCK

Liberty Media

$28.72

-1.54 (-5.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

AUY

Yamana Gold

$3.26

0.09 (2.84%)

18:17
01/17/17
01/17
18:17
01/17/17
18:17
Hot Stocks
Yamana Gold announces resumption of operations at El Penon Mine in Chile »

Yamana Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCJ

Cameco

$13.27

-0.02 (-0.15%)

18:14
01/17/17
01/17
18:14
01/17/17
18:14
Hot Stocks
Cameco down 9.5% after announcing FY16 results will be lower than expected »

In after-hours trading,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.